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Abstract
Bedaquiline (BDQ) has been proven to be effective in the treatment of multidrug-resistant tuberculosis. We hypothesized that
BDQ could be a potential agent to treat nontuberculous mycobacterial (NTM) infection. The objective of this study was to
evaluate the in vitro activity of BDQ against rapidly growing mycobacteria by assessing the minimal inhibitory concentration
(MIC) and minimal bactericidal concentration (MBC) against 18 NTM strains. For MIC determination we performed the
resazurin microtitre assay broth dilution, and for the MBC the c.f.u. was determined. BDQ exhibited a strong inhibitory effect
against most NTM tested; however, for some NTM strains the MBC was significantly higher than the MIC. A new finding is
that Mycobacterium flavescens has a mutation in the gene atpE associated with natural resistance to BDQ. These preliminary
promising results demonstrate that BDQ could be potentially useful for the treatment of NTM.
The genus Mycobacterium comprises more than 150 differ-
ent species of mycobacteria with the capacity to cause patho-
genicity in humans [1]. Most important among these
species, due to their airborne transmission and public health
implications, are Mycobacterium tuberculosis and Mycobac-
terium leprae causing tuberculosis (TB) and leprosy, respec-
tively. Among nontuberculous mycobacteria (NTM),
Mycobacterium avium and Mycobacterium abscessus repre-
sent prevalent sources of infection not only in immunocom-
promised individuals but also in other susceptible
populations, such as in cystic fibrosis patients [2]. More
recently, other emerging NTM, such as Mycobacterium chi-
maera, have been reported as causes of outbreaks due to
heating–cooling devices in surgical rooms [3].
Drug resistance is one of the key issues associated with the
current burden of TB around the world, negatively impact-
ing control of the disease [4, 5]. Consequently, efforts have
been devoted to the discovery and development of new anti-
TB drugs [6]. As a result two new drugs, bedaquiline (BDQ)
and delamanid, were recently approved for the treatment of
multidrug-resistant TB (MDR-TB) [7, 8]. BDQ has a broad
antimycobacterial spectrum and a novel mode of action,
inhibiting the ATP synthase [9]. We hypothesized that
BDQ could also treat NTM infection.
For infections caused by NTM, combination antimicrobial
chemotherapy is the treatment of choice in most cases [10,
11]. Nevertheless, NTM is difficult to eradicate because
most of them are naturally resistant to many common anti-
biotics and in many cases become refractory to the com-
monly recommended antibiotics [12]. In this context, BDQ
has recently been used as off-label for salvage treatment in
patients with Mycobacterium intracellulare lung disease,
with encouraging results [13]. In order to shed light on the
conditions and parameters guiding the potential use of
BDQ for NTM infections, we evaluated its in vitro activity
against a panel of rapidly growing NTM reference strains
and clinical isolates, and explored the possible correlation of
single nucleotide polymorphisms in the target gene and nat-
ural resistance to the drug.
Eighteen rapidly growing mycobacterial strains were used in
this study (Table 1). Seventeen were obtained from the
CCUG collection (http://www.ccug.se) and one strain from
the UCL collection in Brussels, Belgium. Strains were cul-
tured on Löwenstein–Jensen medium and the inoculum was
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prepared in distilled water, adjusted to McFarland 0.5 and
diluted 1 : 10 in Mueller–Hinton (MH) broth medium.
Mycobacterium smegmatis CCUG 28063 was used for qual-
ity control since its minimum inhibitory concentration
(MIC) for BDQ of 0.015 µgml 1 is well known [9]. To
assess whether BDQ had a bacteriostatic or bactericidal
effect, we determined the MIC and minimum bactericidal
concentration (MBC) using the resazurin microplate assay
(REMA) [14, 15]. Briefly, twofold serial dilutions were made
in MH in 96-well polystyrene plates. BDQ concentrations
were 2.0–0.0035 µgml 1 and each experiment was per-
formed in triplicate. An inoculum equal to McFarland 0.5
diluted 1 : 10 was prepared. Growth controls without drug
(positive control), a drug control and a sterile control (nega-
tive control) were also prepared for each assay. To prevent
evaporation during incubation, 200 µl sterile distilled water
was added to all perimeter wells. Plates were sealed and
incubated at 37

C for 3 days before adding 30 µl of 0.01%
resazurin to all wells and incubating for a further 24 h. The
MIC was determined as the lowest drug concentration that
prevented growth and, therefore, a colour change from blue
(oxidized state) to pink (reduced state). MIC values were
scored for each isolate tested. The same plates were used for
MBC determination. At day 4 of incubation and after the
MIC reading, four blue wells were chosen to test the viabil-
ity of the mycobacteria. One hundred microlitres from each
well at the MIC, one concentration higher, and the previous
two BDQ dilutions, were transferred to a tube and diluted
in sterile distilled water to 10 3, 10 4 and 10 5 and plated
in duplicate on Luria broth (LB) agar plates to determine
the c.f.u. Also, c.f.u. were determined in duplicate for the
positive control diluted 10 4, 10 5 and 10 6. The plates
were incubated for 4 days. The percentage of killed bacteria
was calculated against the control, and the MBC was
defined as the lowest drug concentration that killed 99.9%
of bacteria.
For investigation of the mutation in the gene atpE, DNA
extraction was carried out according to Perez-Martinez
et al. [16]. Briefly, a loopful of mycobacteria from a Löwen-
stein–Jensen culture was resuspended in 100 µl Milli-Q
water, boiled for 5min, placed on ice for 10min, centrifuged
at room temperature (13 600 g, 5min) and the supernatants
were used for PCR. The atpE gene was amplified using
degenerated primers atpE forward (degenerated) 5¢-TGTA
YTTCAGCCARGCSATGG-3¢ and atpE reverse (degener-
ated) 5¢-CCGTTSGGDABGAGGAAGTTG-3¢ [17]. How-
ever, if these primers did not amplify atpE, a second set of
primers was used: atpE forward 5¢ -TGTACTTCAGC-
CAAGCGATGG-3¢ and atpE reverse 5¢-CCGTTGGGAA
TGAGGAAGTTG-3¢ [18]. For the degenerated primers, the
PCR was run with an initial pre-denaturation at 95

C for
5min, followed by 30 cycles of denaturation at 95

C for
1min, annealing at 57

C for 1min and elongation at 72

C
for 1min. The reaction was finished with 7min final elonga-
tion at 72

C. Amplicons were detected by agarose (1.5%)
gel electrophoresis and ethidium bromide staining.
For the second set of primers, the PCR was run with an ini-
tial pre-denaturation at 95

C for 5min, followed by 30
cycles of denaturation at 95

C for 1min, annealing at 62

C
for 1min and elongation at 72

C for 1min. The reaction
was finished with 7min final elongation at 72

C.
In both cases, identical primers were used for sequencing
PCR (BigDye Terminator Sequencing Kit; Applied
Table 1. MIC and MBC range for 18 NTM strains
EMBL accession number
for atpE sequences
Collection number, strain reference Species Bedaquiline
MIC (µgml 1) MBC (µgml 1)
LT841272 CCUG 28063, R-50263 Mycobacterium smegmatis 0.015 >2
LT841273 CCUG 28060, R-50260 Mycobacterium phlei 0.07 >2
LT841274 CCUG 41352, R-52136 Mycobacterium duvalii 2 >2
LT841275 CCUG 55442, R-52147 Mycobacterium cosmeticum 0.007 0.015
LT841276 CCUG 25238, R-50254 Mycobacterium mucogenicum 0.062 >0.5
LT841277 CCUG 37665T, R-50255 Mycobacterium neoaurum 2 2
LT841278 CCUG 28064, R-50259 Mycobacterium peregrinum 0.015 >2
LT841279 CCUG 20999T, R-50257 Mycobacterium parafortuitum 0.015 >2
LT841280 CCUG 29050, R-50269 Mycobacterium flavescens >2 >2
LT841281 UCL 22248247, R-50337 Mycobacterum flavescens >2 >2
LT841282 CCUG 31556, R-50246 Mycobacterium fortuitum 0.031 0.062
LT841283 CCUG 39181, R-52149 Mycobacterium mageritense 0.062 >2
LT841284 CCUG 55633, R-52144 Mycobacterium mageritense 0.062 >2
LT841285 CCGU 52054, R-52130 Mycobacterium wolinskyi 0.031 >2
LT841286 CCUG 41449, R-50243 Mycobacterium abscessus 0.062 >2
LT841287 CCUG 27851, R-50244 Mycobacterium abscessus 0.25 >2
LT841288 ATCC 14472, R-50274 Mycobacterium chelonae 0.062 >2
LT841289 DSM 45524T, R-50963 Mycobacterium franklinii 0.062 1
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Biosystems,). Purified products (BigDye XTerminator kit;
Applied Biosystems) were sequenced using the ABI Prism
3130 XL Genetic Analyzer (Applied Biosystems). Sequence
assembly was performed with BioNumerics v. 7.0 (Applied
Maths). Blast sequence software was used to align the wild-
type H37Rv atpE gene (GenBank accession number
NC_000962.3 and GeneID:886937) with the sequences
obtained. Nucleotide alignment was done using ClustalX
version 2.0 software. This alignment was cleaned with Gene-
Doc Version 2.7.000 and translated into protein sequences
and aligned with MEGA version 7.0.21 software.
MIC and MBC results are shown in Table 1. For the major-
ity of strains, BDQ had a significantly higher MBC com-
pared to the respective MIC, suggesting a bacteriostatic
effect. This occurred for Mycobacterium smegmatis, M.
phlei, M. peregrinum, M. parafortuitum, M. mageritense, M.
wolinskyi, M. abscessus and M. chelonae. On the other hand,
M. duvalii and M. neoaurum had a high MIC (2 µgml 1)
without atpE mutation; however, as the other genes of the
ATP synthase operon were not sequenced beside atpE, we
cannot exclude a mutation in one of the other seven genes
of the ATP synthase operon. Interestingly, the BDQ MBC
value was almost equivalent to the MIC for M. cosmeticum
and M. fortuitum. BDQ also showed bactericidal activity
against M. mucogenicum and M. franklini, with an MBC of
0.5 and 1 µgml 1, respectively. The MIC of 0.06 µgml 1 for
M. chelonae is the same as previously described by Huitric
et al. [17]. In the same study they found a BDQ MIC of
0.13–0.25 µgml 1 for M. fortuitum while in this study we
found a lower MIC of 0.03 µgml 1 The MIC of BDQ for M.
mageritense was similar in both studies, at 0.03 (Huitric
et al. [17]) and 0.06 µgml 1 (this study). On the contrary,
M. flavescens was completely resistant to BDQ. Three NTM
species (M. xenopi, M. novocastrense and M. shimoidei)
with significantly higher MICs for BDQ have been described
and are considered naturally resistant to BDQ [17]. Petrella
et al. [19] reported that M. xenopi had a high BDQ MIC
(4 µgml 1), most likely attributed to the polymorphism
seen at amino acid 63 of AtpE. To investigate whether a
similar polymorphism existed and to look into the possible
role of gene mutations on the activity of BDQ against
NTMs, the gene atpE was sequenced in all strains. Fig. 1
shows the amino acid sequence alignment confirming that
the degree of identity at the protein level is very high for all
NTM tested compared to M. tuberculosis H37Rv. An inter-
esting finding of this study is that for M. flavescens, as previ-
ously reported for M. xenopi, M. shimoidei and M.
novocastrense, the alanine at position 63 is replaced by a
methionine. In all other known NTM AtpE sequences, this
alanine is conserved. We confirmed the presence of this
methionine at position 63 by sequencing atpE in one clinical
M. flavescens isolate from St Luc Hospital, Brussels. The
presence of this specific mutation is clearly associated with
resistance to BDQ resulting in a high MIC. Our data show
that the mechanism by which the NTM are inhibited in
their growth (as reflected by their MIC) may be different
from the mechanism by which they are killed (as reflected
by their MBC). BDQ did not show bactericidal activity for
the majority of strains tested. However, we did find BDQ
bactericidal activity for M. cosmeticum, M. mucogenicum,
M. fortuitum and M. franklinii. This finding should be con-
firmed with a larger number of clinical isolates. There is still
more research to be done to explain why the NTM strains
tested are highly sensitive to BDQ and which other factors
besides polymorphisms in AtpE may influence the
NC_000962.3 M. tuberculosis
CU458896.1 M. abscessus
LT841272 M. smegmatis
LT841273 M. phlei
LT841274 M. duvalii
LT841275 M. cosmeticum
LT841276 M. mucogenicum
LT841277 M. neoaurum
LT841278 M. peregrinum
LT841279 M. parafortuitum
LT841280 M. flavescens
LT841281 M. flavescens
LT841282 M. fortuitum
LT841283 M. mageritense
LT841284 M. mageritense
LT841285 M. wolinskyi
LT841286 M. abscessus
LT841287 M. abscessus
LT841288 M. chelonae
LT841289 M. franklinii
Fig. 1. Amino acid alignment of AtpE from selected NTM. Conserved amino acids are represented by dots; only differences among
amino acids are shown with letters. Sequences of wild-type Mycobacterium tuberculosis H37Rv (GenBank accession number
NC_000962.3 and GeneID: 886937) and Mycobacterium abscessus ATCC 19977 (GenBank accession number CU458896.1 and GeneID:
CAM61534.1) were used as controls. The last line indicates the consensus sequence. Sequences of M. flavescens strains R-50269 and
R-50337 are highlighted.
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sensitivity of NTM to BDQ. In addition, more research is
needed to understand why in some species the MIC and
MBC of BDQ are very close and for other species the MBC
is much higher than the MIC, and to elucidate the most
promising companion drugs.
In conclusion, to the best of our knowledge, this is the first
study to have assessed the MIC and MBC values for BDQ
against a large number of rapidly growing NTM. We also
described for the first time that M. flavescens is naturally
resistant to BDQ and its high MIC correlates with the muta-
tion found at amino acid 63 in AtpE (alanine replaced by
methionine). However, despite this finding, BDQ exhibited
a strong inhibitory effect against all NTM tested, suggesting
the potential to treat NTM infections. These preliminary
results warrant further research in this area.
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